Rose Rebecca, Nolan David J, DaRoza Jonathan A, Boye Sanford L, Lamers Susanna L
BioInfoExperts, Alachua, FL 32615, USA.
University of Florida Powell Gene Therapy Center, Gainesville, FL 32605, USA.
Mol Ther Methods Clin Dev. 2025 Jun 2;33(3):101501. doi: 10.1016/j.omtm.2025.101501. eCollection 2025 Sep 11.
To compare the accuracy of three sequencing methods for quantifying point mutations in AAV products, we sequenced the green fluorescent protein (GFP) transgene from two AAV9 reporter vectors (three lots each) and their respective plasmids, using three sequencing approaches: single-template amplification (STA) followed by Sanger sequencing (STA-Sanger) and two next-generation sequencing (NGS) platforms (Illumina and Oxford Nanopore Technologies [ONT]). Similar vector per-base mutation rates were found for both STA-Sanger (0.016%) and Illumina (0.013%), with slightly lower rates in plasmid sequences (STA-Sanger: 0.0019%; Illumina: 0.0074%), whereas ONT per-base mutation rates were much higher (vector: 2.2%; plasmid: 1.3%). The non-reference majority variant frequency (MVF) was more strongly correlated among vector lots for ONT (R = 0.91) compared with Illumina (R = 0.46), although correlation between plasmid and vectors was similar for both platforms (R = 0.23) and virtually non-existent between platforms for the same sample (R < 0.05). Overall, our results showed evidence for single-nucleotide mutations in AAV products, although there was a lack of consistency among sequencing platforms, which underscores the need for the AAV industry to develop sequencing methodologies with improved accuracy as a standard QC protocol.
为了比较三种测序方法在定量腺相关病毒(AAV)产品点突变方面的准确性,我们使用三种测序方法对来自两个AAV9报告载体(各三批)及其各自质粒的绿色荧光蛋白(GFP)转基因进行了测序:单模板扩增(STA)后进行桑格测序(STA-桑格)以及两种新一代测序(NGS)平台(Illumina和牛津纳米孔技术公司[ONT])。STA-桑格测序(0.016%)和Illumina测序(0.013%)在载体上发现的每碱基突变率相似,质粒序列中的突变率略低(STA-桑格测序:0.0019%;Illumina测序:0.0074%),而ONT的每碱基突变率则高得多(载体:2.2%;质粒:1.3%)。与Illumina测序(R = 0.46)相比,ONT测序在载体批次之间的非参考多数变体频率(MVF)相关性更强(R = 0.91),尽管两个平台上质粒与载体之间的相关性相似(R = 0.23),并且同一样本在不同平台之间几乎不存在相关性(R < 0.05)。总体而言,我们的结果显示了AAV产品中存在单核苷酸突变的证据,尽管测序平台之间缺乏一致性,这突出表明AAV行业需要开发准确性更高的测序方法作为标准质量控制方案。